Michael Wasserman

Michael is a Managing Partner at Maverix Private Equity, where his focus is on all aspects of the investment process, along with firm operations and strategy.  Michael leads the firm's healthcare investment practice.  

Prior to joining Maverix, Michael spent 17 years at H.I.G. Capital Management, a leading global private equity investment firm with more than $44 billion of equity capital under management.  Michael remains a Senior Advisor with H.I.G.  Most recently, Michael was a Managing Director of H.I.G. BioHealth Partners, the firm's dedicated healthcare investment fund, where Michael sourced, executed and managed a diverse investment portfolio of healthcare business across stages, sectors and geographies, including HyperBranch  Medical (acquired: Stryker Corporation), NeuWave Medical (acquired: Johnson & Johnson) and VertiFlex Medical (acquired: Boston Scientific) and others.  Michael works closely with management teams and portfolio companies in key areas such as R&D, product development, market access, business development, follow on equity and debt financing and achieving liquidity through M&A or IPO.   

Michael has also founded and held prominent operating roles in several disruptive private equity-backed businesses. Earlier in his career, Michael worked directly for, or as a consultant to, emerging technology businesses, and in the corporate finance, pharmaceutical and clinical research industries.

Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology and Neuroscience from the University of Toronto.  Michael is on the Board of Trustees for the Holland Bloorview Kids Rehabilitation Hospital and the Faculty of Science Advisory Board at McGill University.